Potential therapeutic application DP1 antagonists
| DP1 Antagonist | Route | Dose | Species | Experimental Model | Indication | Reference |
|---|---|---|---|---|---|---|
| Laropiprant | Oral | 37.5 → 300 mg (human dose) | Mice, humans | NA-induced cutaneous vasodilation in mice | Adjunctive therapy for dyslipidemia | Cheng et al., 2006; Paolini et al., 2009 |
| S-5751 | Oral | 30 mg/kg | Sheep | Ascaris suum-induced asthma | asthma | Shichijo et al., 2009 |
NA, nicotinic acid.